Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAAA | Q02083 | 12/20 | 0.48 |
| ▸ | SMO | Q99835 | 1/20 | 0.38 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.37 |
| ▸ | TACR3 | P29371 | 2/20 | 0.36 |
| ▸ | TACR1 | P25103 | 1/20 | 0.36 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.36 |
| ▸ | CNR1 | P21554 | 1/20 | 0.36 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.35 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.35 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2011814 | 0.86 | TACR3 (0.45) | NAAASMOTACR3TACR1KCNH2 | |
| SCHEMBL2014337 | 0.86 | NAAA (0.50) | NAAASMOTACR3TACR1KCNH2 | |
| SCHEMBL2008063 | 0.85 | NAAA (0.49) | NAAASMO | |
| SCHEMBL2010642 | 0.85 | NAAA (0.49) | NAAASMOTACR3TACR1KCNH2 | |
| SCHEMBL2012545 | 0.85 | NAAA (0.49) | NAAASMOTACR3 | |
| SCHEMBL2004262 | 0.83 | SMO (0.53) | NAAASMOTACR3TACR1KCNH2 | |
| SCHEMBL4685415 | 0.83 | SMO (0.52) | NAAASMOTACR3TACR1KCNH2 | |
| SCHEMBL2010870 | 0.82 | TACR3 (0.48) | NAAASMOTACR3TACR1KCNH2 | |
| SCHEMBL2002581 | 0.82 | SMO (0.51) | NAAASMOTACR3TACR1KCNH2 | |
| SCHEMBL3144331 | 0.82 | NAAA (0.48) | NAAASMOCHRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7960556-B2 | Thiadiazole derivatives for the treatment of neuro-degenerative diseases | NV REMYND (BE) | 2011-06-14 | — | — | US | disclosed |
| US-20100144709-A1 | THIADIAZOLE DERIVATIVES FOR THE TREATMENT OF NEURO-DEGENERATIVE DISEASES | NV REMYND (BE) | 2010-06-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100144709-A1 | THIADIAZOLE DERIVATIVES FOR THE TREATMENT OF NEURO-DEGENERATIVE DISEASES | SNCA, PARK7, PRNP | NAAA 2950/4885SMO 1404/4885CHRM1 3769/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.